resTORbio, which is developing novel therapies to improve immune function in the elderly, filed on Friday with the SEC to raise up to $85 million in an initial public offering.
The Boston, MA-based company was founded in 2016 and plans to list on the Nasdaq under the symbol TORC. ResTORrbio filed confidentially on October 27, 2017. BofA Merrill Lynch, Leerink Partners, Evercore ISI and Wedbush PacGrow are the joint bookrunners on the deal. No pricing terms were disclosed.
